Haberler: Kovid-19

Kovid-19

İçinde

("Covid 19","Kovid 19","Koronavirüs","Korona virüs","Biontech","Sinovac","Delta ","Lambda ","Covid19","Kovid19","Covid-19","Kovid-19","Omicron ","Omikron ")

kelimelerinden biri ile,

(" aşı","vaccine","varyant","variant","pandemi","vaka "," dalga","pandemic","salgın")

kelimelerinden birinin aynı anda geçtiği haberler

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021 As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422857

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021 In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422060

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021 The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422061

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021 On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421658

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021 Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421542

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021 In U.S. hospitals during January-March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421438

Cuma, 21 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021 Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421539

Cuma, 21 Ocak 2022, 12:08 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021 This report describes an investigation in Maryland of two linked clusters of COVID-19 cases identified as the B.1.351 variant. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421458

Cuma, 21 Ocak 2022, 12:08 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021 The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416

Cuma, 21 Ocak 2022, 12:08 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021 In a COVID-19 outbreak at a Kentucky skilled nursing facility involving a newly introduced variant to the region, unvaccinated residents and health care personnel (HCP) had 3.0 and 4.1 times the risk of infection as did vaccinated residents and HCP. Vaccine was 86.5% protective against symptomatic illness among residents and 87.1% protective among HCP. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420773